Skip to Content

Clearance of Sunshine Biopharma's anti-cancer compound, Adva-27a, does not involve a toxic intermediate

MONTREAL, Aug. 30, 2011 /PRNewswire/ - Sunshine Biopharma Inc. (OTCBB: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed another study of the mechanism of clearance of its Adva-27a in human liver microsomes in vitro. In the present study, an analysis of the metabolic intermediates generated during the clearance process was performed. The study focused specifically on the generation of Podophyllotoxin, a potentially very toxic intermediate. In addition, the study was performed as a side-by-side experiment in which Adva-27a was compared to Etoposide, a commonly used anti-cancer drug. The results showed that no detectable levels of Podophyllotoxin were produced with Adva-27a over an 80-minute period whereas Etoposide broke down to Podophyllotoxin yielding a steady state concentration of approximately 31 nanomolar Podophyllotoxin in a little over 20 minutes. The release of Podophyllotoxin by Etoposide was found to be Cytochrome P450-dependent whereas no detectable levels were released by Adva-27a in the presence or absence of Cytochrome P450 activity.

"Podophyllotoxin is a Tubulin assembly inhibitor and as such can be very toxic to the cell", said Dr. Steve N. Slilaty, Sunshine's President and CEO. "We are delighted to find that our compound (Adva-27a) does not produce such an undesirable intermediate. This is a significant milestone in our development of Adva-27a, which represents a new hope for cancer patients", he added.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

SOURCE Sunshine Biopharma Inc.


Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464

Posted: August 2011